March 12 (Reuters) – Insulet has recalled specific batches of its insulin-delivery pods in the U.S. after finding a manufacturing defect that could stop diabetic users from getting their full dose of the blood sugar-regulating hormone, the medical device maker said on Thursday.
Shares of the company fell nearly 7% in extended trading.
The company said a small tear in internal tubing can cause insulin to leak inside the device instead of entering the body.
That can lead to high blood sugar levels, and in severe cases, a dangerous condition where the body starts breaking down fat too quickly that needs urgent medical care, Insulet said.
The affected product, the Omnipod 5, is an automated insulin-delivery system that attaches to the skin and delivers insulin to people with diabetes.
Insulet has received 18 reports of serious adverse events, including hospitalizations. No deaths have been reported.
It said only specific lots are affected and that all other devices in the line remain safe to use.
The U.S. Food and Drug Administration has been notified of the issue, the company said.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)
